CDHA CAAR

Note: Check with your organization’s library for availability. “Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials,” by Jaleh Fallah, Lijun Zhang, Anup Amatya, Yutao Gong, Bellinda King-Kallimanis, Vishal Bhatnagar, Chana Weinstock, Daniel L. Suzman, Sundeep Agrawal, Elaine Chang, Mitchell S. Anscher, Dow-Chung Chi, James X. Xu, Jamie R. Brewer, Michael H. Brave, Mehrnoosh Hadadi, Marc R. Theoret, Paul G. Kluetz, Kirsten B. Goldberg, Amna Ibrahim, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani, and Harpreet Singh (Vol. 22, No. 9, September 2021, p. 1230-1239).

www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00334-X/fulltext

“Should Race and Ethnicity Be Factored into Prostate Cancer Screening Guidelines?” by Elizabeth A. Carter, Keith D. Lind, and Pamela E. Morin (April 2017, .pdf format, 7p.).

www.aarp.org/ppi/info-2017/should-race-and-ethnicity-be-factored-into-screening-guidelines.html

“Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study,” by Nina Klemann, M. Andreas Roder, J. Thomas Helgstrand, Klaus Brasso, Birgitte G. Toft, Ben Vainer, and Peter Iversen (Vol. 18, No. 2, February 2017, p. 221-229).

www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30025-6/abstract

“Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy,” by Zhenfei Li, Mohammad Alyamani, Jianneng Li, Kevin Rogacki, Mohamed Abazeed, Sunil K. Upadhyay, Steven P. Balk, Mary-Ellen Taplin, Richard J. Auchus & Nima Sharifi (Vol. 533, No. 7604, May 26, 2016, p. 547-551).

www.nature.com/nature/journal/v533/n7604/abs/nature17954.html

“Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study,” by Neal D. Shore, Simon Chowdhury, Arnauld Villers, Laurence Klotz, D. Robert Siemens, De Phung, Steve van Os, Nahla Hasabou, Fong Wang, Suman Bhattacharya, and Axel Heidenreich (Vol. 17, No. 2, February 2016, p. 153-163).

www.lancet.com/journals/lanonc/article/PIIS1470-2045%2815%2900518-5/abstract

“MiR-187 Targets the Androgen-Regulated Gene ALDH1A3 in Prostate Cancer,” by Irene Casanova-Salas, Esther Masia, Ana Arminan, Ana Calatrava, Caterina Mancarella, Jose Rubio-Briones, Katia Scotlandi, Maria Jesus Vicent, and Jose Antonio Lopez-Guerrero (PLoS ONE 10(5): e0125576. doi:10.1371/journal.pone.0125576, XML, HTML, and .pdf format, 14p.).

journals.plos.org/plosone/article?id=10.1371/journal.pone.0125576

“MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer,” by Gui-Ming Zhang, Chun-Yang Bao, Fang-Ning Wan, Da-Long Cao, Xiao-Jian Qin, Hai-Liang Zhang, Yao Zhu, Bo Dai, Guo-Hai Shi, and Ding-Wei Ye (PLoS ONE 10(4): e0124410. doi:10.1371/journal.pone.0124410, XML, HTML, and .pdf format, 12p.).

journals.plos.org/plosone/article?id=10.1371/journal.pone.0124410

“Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP,” by Susan E. Steck, Lenore Arab, Hongmei Zhang, Jeannette T. Bensen, Elizabeth T. H. Fontham, Candace S. Johnson, James L. Mohler, Gary J. Smith, Joseph L. Su, Donald L. Trump, and Anna Woloszynska-Read (PLoS ONE 10(4): e0125151. doi:10.1371/journal.pone.0125151, XML, HTML, and .pdf format, 15p.).

journals.plos.org/plosone/article?id=10.1371/journal.pone.0125151

“Targeting the MLL complex in castration-resistant prostate cancer,” by Rohit Malik, Amjad P Khan, Irfan A Asangani, Marcin Cieslik, John R. Prensner, Xiaoju Wang, Matthew K. Iyer, Xia Jiang, Dmitry Borkin, June Escara-Wilke, Rachell Stender, Yi-Mi Wu, Yashar S. Niknafs, Xiaojun Jing, Yuanyuan Qiao, Nallasivam Palanisamy, Lakshmi P. Kunju, Pranathi M Krishnamurthy, Anastasia K Yocum, Dattatreya Mellacheruvu, Alexey I. Nesvizhskii, Xuhong Cao, Saravana M Dhanasekaran, Felix Y. Feng, Jolanta Grembecka, Tomasz Cierpicki & Arul M. Chinnaiyan (Vol. 21, No. 4, April 2015, p. 344-352).

www.nature.com/nm/journal/v21/n4/abs/nm.3830.html

A. “Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial,” by Prof. Karim Fizazi, Prof. Howard I. Scher, Prof. Kurt Miller, Ethan Basch, Cora N. Sternberg, Prof. David Cella, David Forer, Mohammad Hirmand, and Prof. Johann S. de Bono (Vol. 15, No. 10, October 2014, p. 1147-1156).

www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70303-1/abstract

B. “Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial,” by J. Athene Lane, Jenny L. Donovan, Michael Davis, Eleanor Walsh, Daniel Dedman, Liz Down, Emma L. Turner, Malcolm D. Mason, Chris Metcalfe, Tim J. Peters, David E. Neal, and Freddie C. Hamdy, for the ProtecT study group (Vol. 15, No. 10, October 2014, p. 1109-1118).

www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70361-4/abstract

“Copy number alteration burden predicts prostate cancer relapse,” by Haley Hieronymus, Nikolaus Schultz, Anuradha Gopalan, Brett S. Carver, Matthew T. Chang, Yonghong Xiao, Adriana Heguy, Kety Huberman, Melanie Bernstein, Melissa Assel, Rajmohan Murali, Andrew Vickers, Peter T. Scardino, Chris Sander, Victor Reuter, Barry S. Taylor, and Charles L. Sawyers (Vol. 111, No. 30, July 30, 2014, .pdf and HTML format, p. 11139-11144). Note: PNAS is providing open access to the full-text of this article.

www.pnas.org/content/111/30/11139.abstract

“Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer,” by Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke, Mathew K. Iyer, Xiaojun Jing, Yi-Mi Wu, Xuhong Cao, Zhaohui S. Qin, Shaomeng Wang, Felix Y. Feng & Arul M. Chinnaiyan (Vol. 510, No. 7504, June 12, 2014, p. 278-282).

www.nature.com/nature/journal/v510/n7504/abs/nature13229.html

“Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer,” by Anna Bill-Axelson, Lars Holmberg, Hans Garmo, Jennifer R. Rider, Kimmo Taari, Christer Busch, Stig Nordling, Michael Haggman, Swen-Olof Andersson, Anders Spangberg, Ove Andren, Juni Palmgren, Gunnar Steineck, Hans-Olov Adami, and Jan-Erik Johansson (Vol. 370, No. 10, March 6, 2014, p. 932-942).

www.nejm.org/doi/full/10.1056/NEJMoa1311593#t=abstract

“Prostate cancer in Australia,” (November 2013, .pdf format, 71p.).

www.aihw.gov.au/publication-detail/?id=60129545134

Note: Medscape requires registration prior to providing access.

“National Evidence on the Use of Shared Decision Making in Prostate-specific Antigen Screening,” by Paul K. J. Han, Sarah Kobrin, Nancy Breen, Djenaba A. Joseph, Jun Li, Dominick L. Frosch, and Carrie N. Klabunde (Annals of Family Medicine, Vol. 11, No. 4, 2013, p. 306-314).

www.medscape.com/viewarticle/807709

“Autonomic Nerve Development Contributes to Prostate Cancer Progression,” by Claire Magnon, Simon J. Hall, Juan Lin, Xiaonan Xue, Leah Gerber, Stephen J. Freedland, and Paul S. Frenette (Vol. 341, No. 6142, July 12, 2013).

www.sciencemag.org/content/341/6142/1236361.abstract

“Prostate Cancer Awareness and Quality Improvement Programme: Improving outcomes for men with prostate cancer,” (May 2013, .pdf and Word format, 27p.).

www.health.govt.nz/publication/prostate-cancer-awareness-and-quality-improvement-programme-improving-outcomes-men-prostate-cancer

“Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study,” by Andrew J Vickers, David Ulmert, Daniel D Sjoberg, Caroline J Bennette, Thomas Bjork, Axel Gerdtsson, Jonas Manjer, Peter M Nilsson, Anders Dahlin, Anders Bjartell, Peter T Scardino, and Hans Lilja (Vol. 346, No. 7907, BMJ 2013;346:f2023, .pdf and HTML format).

www.bmj.com/content/346/bmj.f2023

“Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover,” by Chuandong Geng, Bin He, Limei Xu, Christopher E. Barbieri, Vijay Kumar Eedunuri, Sue Anne Chew, Martin Zimmermann, Richard Bond, John Shou, Chao Li, Mirjam Blattner, David M. Lonard, Francesca Demichelis, Cristian Coarfa, Mark A. Rubin, Pengbo Zhou, Bert W. O’Malley, and Nicholas Mitsiades (Vol. 110, No. 17, Apr. 23, 2013, p.     6997-7002).

www.pnas.org/content/110/17/6997.abstract

“Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity,” by  Zhu A. Wang, Antonina Mitrofanova, Sarah K. Bergren, Cory Abate-Shen, Robert D. Cardiff, Andrea Califano & Michael M. Shen (Vol. 15, No. 3, March 2013, p. 274-283).

www.nature.com/ncb/journal/v15/n3/abs/ncb2697.html

American Journal of Epidemiology (Vol. 176, No. 12, Dec. 15, 2012).

aje.oxfordjournals.org/content/176/12?etoc

Note: Lancet requires free registration prior to providing content. “Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911),” by Michel Bolla, Hein van Poppel, Bertrand Tombal, Kris Vekemans, Luigi Da Pozzo, Theo M. de Reijke, Antony Verbaeys, Jean-Francois Bosset, Roland van Velthoven, Marc Colombel, Cees van de Beek, Paul Verhagen, Alphonsus van den Bergh, Cora Sternberg, Thomas Gasser, Geertjan van Tienhoven, Pierre Scalliet, Karin Haustermans, and Laurence Collette, for the European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups (Vol. 380, No. 9858, December 8, 2012, p. 2018-2027).

www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961253-7/abstract

“Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial,” by James W. Denham, Chantelle Wilcox, David Joseph, Nigel A. Spry, David S. Lamb, Keen-Hun Tai, John Matthews, Chris Atkinson, Sandra Turner, David Christie, Nirdosh Kumar Gogna, Lizbeth Kenny, Gillian Duchesne, Brett Delahunt, and Patrick McElduff (Vol. 13, No. 12, December 2012, p. 1260-1270).

www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2812%2970423-0/abstract

“Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome,” by Paula J. Hurley, Luigi Marchionni, Brian W. Simons, Ashley E. Ross, Sarah B. Peskoe, Rebecca M. Miller, Nicholas Erho, Ismael A. Vergara, Mercedeh Ghadessi, Zhenhua Huang, Bora Gurel, Ben Ho Park, Elai Davicioni, Robert B. Jenkins, Elizabeth A. Platz, David M. Berman, and Edward M. Schaeffer (Vol. 109, No. 37, September 11, 2012, p. 14977-14982).

www.pnas.org/content/109/37/14977.abstract?etoc

“Genetic Association of the KLK4 Locus with Risk of Prostate Cancer Felicity Lose,” Srilakshmi Srinivasan, Tracy O’Mara, Louise Marquart, Suzanne Chambers, Robert A. Gardiner, Joanne F. Aitken, the Australian Prostate Cancer BioResource, Amanda B. Spurdle, Jyotsna Batra, and Judith A. Clements (PLoS ONE 7(9): e44520. doi:10.1371/journal.pone.0044520, XML, HTML, and .pdf format, 14p.).

www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0044520

“Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy,” by Juanita M. Crook, Christopher J. O’Callaghan, Graeme Duncan, David P. Dearnaley, Celestia S. Higano, Eric M. Horwitz, Eliot Frymire, Shawn Malone, Joseph Chin, Abdenour Nabid, Padraig Warde, Thomas Corbett, Steve Angyalfi, S. Larry Goldenberg, Mary K. Gospodarowicz, Fred Saad, John P. Logue, Emma Hall, Paul F. Schellhammer, Keyue Ding, and Laurence Klotz (Vol. 367, No. 10, September 6, 2012, p. 895-903).

www.nejm.org/doi/full/10.1056/NEJMoa1201546#t=abstract

“Quality-of-Life Effects of Prostate-Specific Antigen Screening,” by Eveline A.M. Heijnsdijk, Elisabeth M. Wever, Anssi Auvinen, Jonas Hugosson, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Arnauld Villers, Alvaro Paez, Sue M. Moss, Marco Zappa, Teuvo L.J. Tammela, Tuukka Makinen, Sigrid Carlsson, Ida J. Korfage, Marie-Louise Essink-Bot, Suzie J. Otto, Gerrit Draisma, Chris H. Bangma, Monique J. Roobol, Fritz H. Schroder, and Harry J. de Koning (Vol. 367, No. 7, August 16, 2012, p. 595-605).

www.nejm.org/doi/full/10.1056/NEJMoa1201637